The Technical Analyst
AXIM Biotechnologies, [AXIM]
Exchange: PNK Industry: Biotechnology
AXIM Biotechnologies, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-6.15% $0.0115
America/New_York / 3 mai 2024 @ 15:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.19 mill |
| EPS: | -0.0400 |
| P/E: | -0.290 |
| Earnings Date: | May 22, 2024 |
| SharesOutstanding: | 278.43 mill |
| Avg Daily Volume: | 0.558 mill |
| RATING 2024-05-03 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.290 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.290 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0095 - 0.0135 ( +/- 17.47%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-15 | Huemoeller John Walter Ii | Buy | 250 000 | Convertible Note |
| 2024-03-15 | Valencia Catalina | Buy | 7 837 500 | Convertible Note |
| 2024-03-15 | Schroeder Blake | Buy | 35 000 | Convertible Note |
| 2024-03-15 | Cunningham Robert L | Buy | 35 000 | Convertible Note |
| 2024-03-15 | Scott Timothy Richard | Buy | 35 000 | Convertible Note |
| INSIDER POWER |
|---|
| 100.00 |
| Last 56 transactions |
| Buy: 36 148 017 | Sell: 23 000 000 |
Forecast:
16:00 - $0.0115
Live Trading Signals (every 1 min)
Forecast
1: 15:40 - $0.0120
Forecast 2: 16:00 - $0.0115
Forecast 3: 16:00 - $0.0115
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0115 (-6.15% ) |
| Volume | 0.632 mill |
| Avg. Vol. | 0.558 mill |
| % of Avg. Vol | 113.15 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AXIM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AXIM
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation. It is also developing rapid quantitative tear tests for Matrix metalloproteinase-9, an inflammatory biomarker for dry eye disease; SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
Latest Press Releases
2024-03-27 09:00:00 - Press Release
Video: Axim Biotechnologies Ceo Presents At Benzinga Virtual Healthcare Summit 2024
Company ceo john huemoeller ii interviewed by tony noto on axim's diagnostic research programs in dry eye disease and parkinson's
2024-02-20 09:00:00 - Press Release
Axim® Biotechnologies' Tear Based Testing Platform Continues To Gain Traction After Successful Clinical Validation
The company's commercialization partner versÉa ophthalmic places re-stock order of axim's digital assay reader san diego, ca, feb. 20, 2024 (globe newswire) -- via newmediawire – axim biotechnologies, inc . (otcqb: axim) (“axim biotech,” “axim” or “the company”), an international healthcare diagnostic solutions development company, announced today that the company has received an additional order for its electronic readers designed to analyze both of the company's proprietary diagnostics assays from its commercialization partner versÉa ophthalmics.
2023-12-20 09:00:00 - Press Release
Axim® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision To Scale Assay Production
Leading diagnostic healthcare company signs contract manufacturing agreement in order to fulfill sales of ige and lactoferrin ded diagnostic assays
2023-08-01 09:00:00 - Press Release
Axim® Biotechnologies Receives Notice Of U.s. Patent Allowance For Three Separate Patents Including Its Rapid Point Of Care Neutralizing Antibody Test
San diego--(business wire)--axim biotechnologies, inc. (otcqb: axim) (“axim biotech,” “axim” or “the company”), an international healthcare diagnostic solutions development company, announced today the receipt of notification by the united states patent & trademark office of several patent allowances. axim has been developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including, for example, sars-cov-2, lactoferrin, ige, lacritin, mmp-9. this inn.
2023-07-12 13:36:00 - Press Release
Update: Axim® Biotechnologies Starts Shipping Revenue Generating Ige Diagnostic Validation Assays To Customers Nationwide
Leading diagnostic healthcare company also announces over 50 initial clinic commitments for its full diagnostic assay platform
Latest News
2021-10-12 09:00:00 - GlobeNewsWire
AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced the development of the second generation version of its Rapid Neutralizing Antibody Test for COVID-19.
2021-10-11 09:00:00 - GlobeNewsWire
AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisory Board
Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board
2021-10-05 09:00:00 - GlobeNewsWire
AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board
Dr. Periman Joins Chairman Joseph Tauber as Advisory Board's Second Member Dr. Periman Joins Chairman Joseph Tauber as Advisory Board's Second Member
2021-09-15 09:26:00 - GlobeNewsWire
AXIM® Biotech Appoints Ophthalmic Industry Veteran Jeff Busby as Senior VP Business Development
Busby to Direct Dry Eye Disease Commercial Launch for Recently Acquired Diagnostic Tech Busby to Direct Dry Eye Disease Commercial Launch for Recently Acquired Diagnostic Tech
2021-08-30 09:00:00 - GlobeNewsWire
AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA for its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations
SAN DIEGO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease diagnostics, announced today that the Company's manufacturing partner Empowered Diagnostics has filed an amended emergency use authorization (EUA) with the Food and Drug Administration (FDA) for ImmunoPass™, the Company's rapid test that detects COVID-19 neutralizing antibodies at point-of-care locations.
2021-05-05 08:12:00 - GlobeNewsWire
AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files for Approval for Use of Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations in Canada and the EU
SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company's manufacturing partner Empowered Diagnostics has filed for emergency approval to use ImmunoPass™, the Company's rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies, to detect COVID-19 neutralizing antibodies in whole blood at point-of-care locations throughout Canada and the EU.
2021-03-08 09:00:00 - GlobeNewsWire
AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has successfully completed point-of-care clinical trials on its much awaited ImmunoPass rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies to help understand COVID-19 immunity, validate vaccine's effectiveness and estimate how long the vaccine will be effective in patients.